Trial Profile

A Phase 1, Multi-Tumor, Bioavailability Study of Relatlimab in Combination With Nivolumab

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Relatlimab (Primary) ; Hyaluronidase
Indications Adenocarcinoma; Bladder cancer; Carcinoma; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Bristol-Myers Squibb

Most Recent Events

04 Apr 2023 Status changed from active, no longer recruiting to completed.
13 Sep 2021 Planned primary completion date changed from 18 Aug 2022 to 17 Aug 2022.
13 Sep 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com